Nano-based delivery of RNAi in cancer therapy

Molecular Cancer

Review

Guan Jiang¹  Yong Xin²  Min Huang²  Qian Huang²  Long zhen Zhang²  Wen Wen Guo² 

[1] Department of Dermatology, Affiliated Hospital of Xuzhou Medical University, 221002, Xuzhou, China;Hospital of Xuzhou Medical University, 221002, Xuzhou, Jiangsu, People’s Republic of China;

关键词: Nanocarriers;    RNAi;    siRNA;    miRNA;    Cancer therapy;    Gene therapy;   

DOI  :  10.1186/s12943-017-0683-y

 received in 2017-02-17, accepted in 2017-06-20,  发布年份 2017

来源: Springer

【 摘 要 】

BackgroundRNA interference (RNAi), a newly developed method in which RNA molecules inhibit gene expression, has recently received considerable research attention. In the development of RNAi-based therapies, nanoparticles, which have distinctive size effects along with facile modification strategies and are capable of mediating effective RNAi with targeting potential, are attracting extensive interest.ObjectiveThis review presents an overview of the mechanisms of RNAi molecules in gene therapy and the different nanoparticles used to deliver RNAi molecules; briefly describes the current uses of RNAi in cancer therapy along with the nano-based delivery of RNA molecules in previous studies; and highlights some other carriers that have been applied in clinical settings. Finally, we discuss the nano-based delivery of RNAi therapeutics in preclinical development, including the current status and limitations of anti-cancer treatment.ConclusionWith the growing number of RNAi therapeutics entering the clinical phase, various nanocarriers are expected to play important roles in the delivery of RNAi molecules for cancer therapeutics.

【 授权许可】

CC BY   
© The Author(s). 2017